(RTTNews.com) - Novartis (NVS) said that it reached a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug candidates that are part of the Novartis Infectious Diseases portfolio, which have the potential to address the need for new agents to treat antibiotic resistant Gram-negative infections.
Antibiotic resistance is widely recognized as a major public health threat and innovative candidates to combat drug resistant bacteria remain a critical unmet need. Both the Centers for Disease Control and Prevention or CDC, and the World Health Organization (WHO) have identified CRE and drug resistant Pseudomonads as serious threats that pose significant risk to human health.
As per the terms of the agreement, Boston Pharmaceuticals acquired worldwide rights to two complementary candidates targeting carbapenem-resistant enterobacteriaceae or CRE and one candidate targeting Pseudomonas infections.
Novartis will receive an upfront payment and is entitled to royalties and milestone payments for successfully commercialized medicines. In addition, Novartis will receive an equity stake in two new companies formed together with Boston Pharmaceuticals to further develop and commercialize these programs. Financial terms of the agreement were not disclosed.
Novartis noted that it continues to discover and develop new medicines to treat tropical diseases through research at the Novartis Institute for Tropical Diseases (NITD). In addition, earlier this year the company announced a five-year $100 million commitment? to advance the Novartis malaria pipeline through 2023 and to complete a comprehensive global clinical trial program for two novel antimalarial drug candidates KAF156 and KAE609.
Read the original article on RTTNews (http://www.rttnews.com/2940341/novartis-licenses-three-novel-anti-infective-programs-to-boston-pharma.aspx)
For comments and feedback: contact email@example.com